$KYTX SEC Filings

Filed On	Filing
19 Oct 2026	SCHEDULE 13G
24 Sep 2026	8-K: Regulation FD Disclosure Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	10-Q
11 Aug 2026	8-K: Results of Operations and Financial Condition
29 Jul 2026	SCHEDULE 13G
27 Jul 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
09 Jul 2026	8-K: Entry into a Material Definitive Agreement
02 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
29 May 2026	Form 4: Clark Ian T, Director Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)
29 May 2026	Form 4: Cohen Fred E, Director Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)
29 May 2026	Form 4: Seidenberg Beth C, Director Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)
29 May 2026	Form 4: Shaw Christi, Director Gave up 4,194 shares to cover exercise price or tax ($36K)
29 May 2026	Form 4: Aktar Mert, Director Received 5,093 shares as a grant or award · Granted 20,582 Stock Option (right to buy)
20 May 2026	Form 4: Martini Gregory S., Chief Financial Officer Granted 325,000 Stock Option (right to buy)
20 May 2026	Form 3: Martini Gregory S., Chief Financial Officer No securities owned
18 May 2026	8-K: Departure/Election of Directors or Officers; Compensation; Other Events
12 May 2026	10-Q
12 May 2026	8-K: Results of Operations and Financial Condition
06 May 2026	Form 4: Dac Nadia, Chief Commercial Officer Granted 300,000 Stock Option (right to buy)

Comments